LFB USA is led by a team of business experts and scientists with a successful track record of developing and commercializing important and highly innovative healthcare technologies and life-changing therapeutics.
Jose Antonio Moreno Toscano
Chief Executive Officer
Jose Antonio Moreno Toscano is the current LFB USA & rEVO Biologics Chief Executive Officer, bringing significant global leadership experience to the Company.
Prior to joining LFB, Jose served as President of Safe Harbor Compliance and Clinical Services, where he is also a Board member. He also led the US & Canadian subsidiaries of ALK, a publicly held Danish company that is the world leader in allergy and immunotherapy care. He held full P&L and operational responsibility for ALK’s Americas region, successfully growing the top and bottom line via both organic growth and accretive acquisitions. Prior to his role at ALK, Jose served as Chief Financial Officer for Applus A/S in Copenhagen. He began his career in Corporate Development and Investor Relations, where he led M&A activities at Chr. Hansen Holding, a world leader in biosciences focused on developing and commercializing ingredients for the food, agricultural and pharmaceutical industries.
Jose brings a global perspective to our business, having lived and worked in several European countries as well as the US. Jose earned his Master’s Degree in Law from the Universidad de Murcia in Spain and his MBA in International Finance and Strategy from the ENPC School of International Management in Paris.
William Gavin, D.V.M.
Chief Operating Officer
Dr. Gavin has held various positions of increasing responsibility within the Company since 1994, including President. Prior to becoming Chief Operating Officer, he was Senior Vice President of Operations and responsible for the company’s production programs and transgenic animal development as well as many of the Operational components within the company including Farm Operations, Dairy Operations, Veterinary Services, Facilities, Occupational Health and Safety, Security and Logistics. Dr. Gavin has been with the company for 20+ years and working in this field and with this platform of production for 25+ years. Dr. Gavin is well published, presents internationally, and is also named on numerous international patents. He was instrumental in the development of the production facility in central Massachusetts and responsible for overseeing the site through to the first ever Regulatory approval and licensure for the rPRO Technology™ by the EMA, FDA-CBER and FDA-CVM. He holds a Bachelors degree in Animal Science with honors from the University of Massachusetts and a Doctorate in Veterinary Medicine with honors from Tufts University.
Vice President, General Counsel & Compliance
Christopher Williams joined LFB-USA in October of 2017 as Vice President, General Counsel and Compliance Officer. He brings over 15 years of legal and corporate business experience at prominent local law firms and private corporations.
Mr. Williams was most recently employed as Senior Counsel at Sunovion Pharmaceuticals. Prior to that he was Legal Counsel for Linedata Services North America, and previously, General Counsel & Senior Vice President of Operations for Survey.Com.
Mr. Williams began his legal career as a summer associate and later an associate at Bingham Dana LLP (later acquired by Morgan Lewis) and was also an associate at Goulston & Storrs PC and Goodwin Procter LLP, before transitioning to the business sector. He holds a Juris Doctor degree from the Georgetown University Law Center and a Bachelor of Arts in International Studies from Emory University where he was an All American in Track and Field and was enshrined in the Emory University Sports Hall of Fame.
Mr. Williams is licensed to practice in MA and is a former Co-Chair of the Boston Bar Association International Law Section.
Charli Sanders, MD
Senior Vice President, Regulatory Affairs
Dr. Charli Sanders joined LFB USA as Senior Vice President, Regulatory Affairs in January 2018. Dr. Sanders brings extensive strategic regulatory affairs, medical, and pharmacovigilance expertise to LFB-USA that includes more than 18 years of pharmaceutical management experience. Her experience in global drug development, clinical research and regulatory affairs includes interactions world-wide with regulators, scientific leaders, and major pharmaceutical/biotech companies. Dr. Sander’s therapeutic experience in oncology, neuroscience, analgesia, immunology and pediatrics is well-aligned with our innovative therapeutic focus.
Dr. Sanders trained in Pediatrics and has held teaching faculty appointments at the Children’s Hospital of Los Angeles (USC), Morgan Stanley Children’s Hospital (Columbia University Medical Center), Children’s Hospital of Boston (Harvard University) and Yale University. She received her Medical Degree from the University of Pennsylvania School of Medicine and as well as her undergraduate degree through Penn's University Scholars' Program which enabled her to conduct early nonclinical translational research in demyelination disorders of the central and peripheral nervous systems.
Prior to joining LFB USA, Dr. Sanders was Senior Vice President, Global Regulatory Affairs for Kadmon Pharmaceutical Holdings, Inc. where she was responsible for Global Medical and Regulatory Affairs including strategic, clinical, CMC and pharmacovigilance compliance. Prior to Kadmon, Dr. Sanders was employed as Vice President Global Regulatory Affairs, Compliance and Medical Writing at Premier Research. In her capacity as VP at Premier, Dr. Sanders represented small-to-large pharma/device companies in their quests to attain first-to-market product authorizations and commercialization of their medical and health care products. Dr. Sanders’ formative industry career achievements included successful advancing strategic regulatory and product development leadership roles at Merck Sharp & Dohme (MSD), Daiichi Sankyo, and Barr-Duramed (Teva). Dr. Sanders is able to leverage her broad career experiences, both in global medical and regulatory management to bring a wealth of knowledge to the LFB organization.